Created with Sketch.
The Evidence Based Rheumatology Podcast
7 minutes | 3 months ago
E69: Publication Trends in SRMAs and RCTs
This week I cover another of my meta-research projects, this one on systematic review and meta analysis (SRMA) growth as compared to randomized clinical trial (RCT) growth. Short and to the point - hope you enjoy! I highly recommend checking out the associated graphs - just take a quick peek at some point while listening. Find them on my twitter handle @ebrheum
14 minutes | 3 months ago
E68: SELECT-CHOICE Upadacitinib vs Abatacept in RA
Active comparator trial! Always my favorite. Lots of fun topics in this one, including noninferiority trials, crafty endpoints, and PROs. Check it out and let me know what you think! @ebrheum
16 minutes | 4 months ago
E67: Belimumab in Lupus Nephritis (BLISS-LN)
Another day, another lupus trial, another round of endpoint shenanigans. Why does that matter? How big is the benefit from belimumab in SLE nephritis? Will this save lives and prevent ESRD / RRT? I try to tackle these issues this week and (hopefully) avoid getting myself in trouble. Hope you enjoy the episode! Let me know what you think @ebrheum on twitter!
14 minutes | 4 months ago
E66: MRI to Diagnose PMR
Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message. Also, check out the "2-5-10" rule that I referenced! This is required reading for anyone who rotates with me - easily one of the most useful EBM papers I have ever read.
7 minutes | 5 months ago
E65: Anifrolumab in SLE - A Reply
Quick podcast this week that expands on issues I discuss in Episode 55. Go back and listen to that one first if you have time! I think this is an important issue and it's one I'd like to highlight. Let me know what you think @ebrheum and please share with friends!
3 minutes | 5 months ago
E65: Anifrolumab for SLE - A Reply
This week I wanted to share a letter I wrote to NEJM and discuss PROs in the anifrolumab trials. It's a quick little episode before next week when I'm hoping to dig into a fascinating paper about MRIs and PMR!
11 minutes | 5 months ago
E64: Antirheumatic Disease Therapies: A Systematic Review and Meta Analysis
This week I wanted to share a recent systematic review and meta analysis, which was published by myself and a group on behalf of the Global Rheumatology Alliance. I use this as an opportunity to close out a few issues and describe the current landscape. After this I'm planning to go back to good old rheumatology-based podcasts for a few months!
3 minutes | 5 months ago
E63: Housekeeping #3
The podcast is back! I tune in briefly here to explain where I've been, what I'm doing, and where this will be headed. Feel free to skip right ahead if you'd rather just dig back in!
20 minutes | 9 months ago
E62: COVID19 Series - Hydroxychloroquine #3
Back this week to update you on the data for hydroxychlorquine. There has been a lot of action - and very little resolution - to this issue since my last episode. Let me know what you think, follow along on twitter @ebrheum and get the papers themselves at ebrheum.com.
17 minutes | 10 months ago
E61: COVID19 Series - IL6 #1
Diving into a new "rheum treatments for COVID" topic today - IL6 inhibition. It took me awhile to get to this, in part because the hydroxychloroquine situation has been something to behold and in part because there's just nothing to say. I cover two case series here, neither of which are strong evidence. Hope you enjoy! Follow me @ebrheum to let me know what you think!
10 minutes | 10 months ago
E60: COVID19 Series - Hydroxychloroquine #2
Trying to get to IL6, but so much happening in the world of hydroxychloroquine. As I said at the beginning, things are likely to move fast. I'm planning to make this as an extended series, so please go back and listen to #1 before you listen to this! This episode will round out the paper by Gautret et al. and discuss the best copy of a paper by Jun et al. that I've been able to find. Follow me @ebrheum and share with friends!
20 minutes | 10 months ago
E59: COVID19 Series - Hydroxychloroquine v1
Welcome to the first episode of my series on immunosuppressive treatments for COVID-19. Today I cover the Renault trial and a nice systematic review, which I believe are the two best options in the published literature to date. Find the papers and ways to subscribe at ebrheum.com and follow me on twitter @ebrheum
3 minutes | 10 months ago
E58: Brief Update - Podcasting in the Era of COVID-19
Quick update podcast. I'm planning to tweak the format of my podcast to better respond to COVID-19. I'll be doing more or less the same thing but with a different structure and focus. It seems a little peculiar to discuss anything else during the current crisis, so I intend to refocus and hope to offer value to listeners. Share with friends - ebrheum.com and @ebrheum
16 minutes | a year ago
E57: PEXIVAS Trial - PLEX and Reduced Steroid in ANCA Vasculitis
PEXIVAS has landed! This week I go over the trial and my take on it's results. Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum!
11 minutes | a year ago
E56: Continue or Withdraw Prednisone in SLE (CORTICOLUP)
(Yet) another RCT this week! Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a separate common problem in trials!
18 minutes | a year ago
E55: Anifrolumab for SLE (TULIP 1&2)
This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE. Great to see a new drug in this disease state; interesting to think through how these trials played out. Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback!
17 minutes | a year ago
E54: Rheum4Debate - Triple Tx is 1st Line in RA w/No Response to MTX
Happy New Year! This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line." Please be sure to VOTE AGAIN on twitter (@ebrheum) after you have listened!
15 minutes | a year ago
E53: Another Look at Nintedanib for SSc-ILD
This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD. The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/
9 minutes | a year ago
E52: HOPE RCT - Prednisone for OA of the Hand
Surprising RCT this week discussing the HOPE trial, which pitted 10mg prednisone against placebo for inflammatory hand OA. I do think this will change my practice, but in a far narrower sense than the headline would suggest. Check it out and find all my other content at ebrheum.com!
18 minutes | a year ago
E51: Rheum4Debate - "Start TCZ Upfront in GCA"
Rheum4Debate is back! This week we have Dr. Anisha Dua arguing in support of the motion, "Patients with newly diagnosed GCA should start glucocorticoids WITH tocilizumab over glucocorticoids alone." I argue against the motion and Dr. Sarah Fantus was kind enough to moderate. In our pre-debate poll, 51% supported the motion, 34% disagree with the motion, and 15% were undecided. Please be sure to vote in the post-debate motion on twitter as well! Find me @ebrheum, Dr. Dua @anisha_dua, and Dr. Fantus @sarahfantus.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2020